CYP3A
“Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients”. Pharmacogenomics 7 (4): 563–74. doi:10.2217/14622416.7.4.563. PMID 16753004.
Rais N, Chawla YK, Kohli KK (2007). “CYP3A phenotypes and genotypes in North Indians”. Eur. J. Clin. Pharmacol. 62 (6): 417–22. doi:10.1007/s00228-006-0105-3. PMID 16758258.
Kirby B, Kharasch ED, Thummel KT et al. (2007). “Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities”. Journal of clinical pharmacology 46 (11): 1313–9. doi:10.1177/0091270006292625. PMID 17050796.
He P, Court MH, Greenblatt DJ, von Moltke LL (2007). “Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity”.
Pharmacogenetics 11 (2): 111–21. doi:10.1097/00008571-200103000-00002. PMID 11266076.
Miyazawa M, Shindo M, Shimada T (2002). “Roles of cytochrome P450 3A enzymes in the 2-hydroxylation of 1,4-cineole, a monoterpene cyclic ether, by rat and human liver microsomes”. Xenobiotica 31 (10): 713–23. doi:10.1080/00498250110065595. PMID 11695850.
Reid JM, Kuffel MJ, Ruben SL et al. (2002). “Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans”. Clin. Cancer Res. 8 (9): 2952–62. PMID 12231541.
Martínez C, García-Martín E, Pizarro RM et al. (2002). “Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy”.